Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma
Thomas B. Casale(University of South Florida), Nicola A. Hanania(Baylor College of Medicine), S Greenberg(Novartis (United States)), Theodore A. Omachi(University of California, San Francisco), Bradley E. Chipps, Benjamin Trzaskoma(MDS Associates (United States)), Karin Rosén(Baylor College of Medicine), Tmirah Haselkorn
Cited by 156
Related Papers
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision
|Journal of Allergy and Clinical Immunology|2017|2k
An Official American Thoracic Society/European Respiratory Society Statement: Asthma Control and Exacerbations
|American Journal of Respiratory and Critical Care Medicine|2009|1.9k
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 Revision
|Journal of Allergy and Clinical Immunology|2010|1.8k
Lebrikizumab Treatment in Adults with Asthma
|New England Journal of Medicine|2011|1.5k
Asthma endotypes: A new approach to classification of disease entities within the asthma syndrome
|Journal of Allergy and Clinical Immunology|2011|1.2k